FDA Approves First Drug To Treat Rare Form Of Muscular Dystrophy
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
Drugs
1,221 - 1,240 of 1,303 Results
-
-
Candidates Decry High Drug Prices, But They Have Few Options For Voters
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
By Julie Rovner -
The Ads Say ‘Get Your Flu Shot Today,’ But It May Be Wiser To Wait
The flu vaccine is available for longer windows of time. Experts say to weigh convenience and science in deciding when to roll up your sleeve.
-
Geographic, Racial Disparities In Stroke Treatment Tracked In New Study
Patients living in the Northeast are more than twice as likely to get a powerful drug than those in the Midwest or South and African-Americans were 26 percent less likely to get the medicine, a study in the journal Neurology finds.
-
Study: Health Spending Related To Opioid Treatment Rose More Than 1,300 Percent
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
-
Consumer Group Questions Role of Drug Costs In California Premium Hikes
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
By Chad Terhune -
Behind The EpiPen Monopoly: Lobbying Muscle, Flailing Competition, Tragic Deaths
A closer look shows that industry lobbying was just one factor in EpiPen’s sales explosion.
-
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
-
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
-
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
-
DIAGNOSIS: UNPREPARED
‘America’s Other Drug Problem’: Copious Prescriptions For Hospitalized Elderly
Older people are often given a huge number of medications, and many of them are unnecessary or even harmful.
By Anna Gorman -
Screening Positive For Depression Doesn’t Mean You’ll Get Treatment, Study Finds
A study in JAMA Internal Medicine suggests that patients known as the “worried well” are actually the highest utilizers of mental health care — and likely to receive antidepressants.
By Zhai Yun Tan -
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
-
California Lawmaker Pulls Plug On Drug Price Transparency Bill
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
-
People With Obamacare Plans Filled More Prescriptions, But Had Lower Costs
A study explores how coverage gains resulting from the federal health law may have changed people’s health care habits and spending.
-
Insurance Rules Can Hamper Recovery From Opioid Addiction
Medicaid and other health insurers require doctors to file time-consuming paperwork before allowing them to prescribe drugs that help people quit opioids. That delay fosters relapse, specialists say.
-
Syncing Up Drug Refills: A Way To Get Patients To Take Their Medicine
A study published in Health Affairs concludes that the idea of coordinating prescription refill timelines for people with multiple chronic conditions could improve their medication adherence and health outcomes.
-
Teaching Future Doctors About Addiction
Most medical schools offer very little education on treating opioid addiction. Stanford University's medical school is trying to ramp it up.
-
Study Bodes Well For Biosimilars But Highlights Need For More Research
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.
-
Opioid Dependence Leads To ‘Tsunami’ Of Medical Services, Study Finds
Insurance claims for medical services related to opioid dependence diagnoses rose more than 3,000 percent between 2007 and 2014, an analysis finds.